Parallel-group 8-week study on chlorthalidone effects in hypertensives with low kidney function

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Hypertension management in patients with reduced kidney function remains a clinical challenge.
• The short-term effects of chlorthalidone in this population are not well-established.
• Chlorthalidone is a thiazide-like diuretic commonly used to treat hypertension.

Purpose of the Study:

• To evaluate the short-term efficacy and safety of chlorthalidone in hypertensive patients with low kidney function.
• To compare blood pressure reduction and adverse event incidence between patients with and without low kidney function.

Main Methods:

• An 8-week, open-label study comparing 25-mg chlorthalidone added to existing treatment.
• Two groups were studied: those with estimated glomerular filtration rate <60 mL/min×1.73 m(2) (low kidney function) and controls (eGFR ≥60 mL/min×1.73 m(2)).
• Blood pressure, estimated glomerular filtration rate, serum potassium, and uric acid levels were monitored.

Main Results:

• Both groups experienced significant blood pressure reduction without significant between-group differences.
• Incidence of adverse events was similar between the low kidney function and control groups.
• Estimated glomerular filtration rate and serum potassium decreased, while serum uric acid increased in both groups.

Conclusions:

• Short-term chlorthalidone treatment is effective and safe in hypertensive patients with low kidney function.
• Reduced kidney function did not diminish the blood pressure-lowering effects of chlorthalidone.
• Chlorthalidone can be considered a viable treatment option for hypertension in patients with impaired renal function.